Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
solasia.co.jp

See what CB Insights has to offer

Stage

IPO | IPO

Total Raised

$7.8M

Date of IPO

3/23/2017

Market Cap

14.02B

About Solasia Pharma

Solasia Pharma, formerly known as JapanBridge, expedites patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. Solasia has Asian rights to Sancuso (extended release granisetron transdermal patch) from ProStrakan Group plc and an exclusive license to ZIOPHARM's SP-02 / darinaparsin, in major Asian countries. Solasia is currently conducting a Phase 1 study of darinaparsin in PTCL in Japan and Korea.

Solasia Pharma Headquarter Location

3F, Shiodome Building 1-2-20, Kaigan, Minato-ku,

Tokyo, 105-0022,

Japan

+81 3 6721 8332

Latest Solasia Pharma News

Solasia and Nippon Kayaku Announce License Agreement in Japan for New Drug Candidate DARINAPARSIN (SP-02)

Nov 2, 2021

TOKYO--(BUSINESS WIRE)--Solasia Pharma K.K. (TOKYO: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) and Nippon Kayaku Co., Ltd. (TOKYO: 4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto) today jointly announced the conclusion of a license agreement for marketing rights to darinaparsin (generic name, development code: SP-02) in Japan (hereinafter “this agreement”). Darinaparsin is a drug candidate under development by Solasia for rela...

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Solasia Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Solasia Pharma is included in 2 Expert Collections, including Cancer.

C

Cancer

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

5,882 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Solasia Pharma Patents

Solasia Pharma has filed 5 patents.

The 3 most popular patent topics include:

  • Antineoplastic drugs
  • Arsenic compounds
  • Experimental cancer drugs
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/27/2014

11/24/2020

Transcription factors, Antineoplastic drugs, Experimental cancer drugs, Organoarsenic compounds, Oncology

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/27/2014

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/24/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Transcription factors, Antineoplastic drugs, Experimental cancer drugs, Organoarsenic compounds, Oncology

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Solasia Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Solasia Pharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.